Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsing-remitting MS (RRMS) or secondary-progressive MS (SPMS)
Previous treatment with disease modifying drugs
Adjustment of disease modifying treatment necessary at the discretion of the investigator
Switch to Betaferon at least 1 month but not longer than 3 months prior to inclusion
You may not be if
Patients not fulfilling the indications in the local prescribing information
Refusal to sign inform consent
Clareo Health | Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
